Reimbursement for Givlaari – With Price Drop – Urged for Canada

Reimbursement for Givlaari – With Price Drop – Urged for Canada

310428

Reimbursement for Givlaari – With Price Drop – Urged for Canada

The Canadian Agency for Drugs and Technology in Health, called CADTH, has recommended that Givlaari (givosiran) be reimbursed by public plans — if certain conditions are met — when it’s used to treat adults with acute hepatic porphyria (AHP). One condition, according to CADTH, is that the therapy’s cost should be reduced by more than half. CADTH is an independent body that relays evidence to Canada’s healthcare decision-makers to help them make informed judgments about…

You must be logged in to read/download the full post.